Preventing Pregnancies for Patients on Teratogenic Medications
Preventing Pregnancies for Patients on Teratogenic Medications https://pediatricsnationwide.org/wp-content/uploads/2019/05/AdobeStock_91559062-header-1024x575.jpg 1024 575 Emily Siebenmorgen https://pediatricsnationwide.org/wp-content/uploads/2023/05/Emily.Siebenmorgen-scaled-e1684876333147.jpg
In a recent study from Nationwide Children’s Hospital, researchers increased the time between pregnancies for patients on teratogenic medications from an average of 52 days to over 900 days through quality improvement (QI) and behavioral economics. Teratogenic medications such as methotrexate and mycophenolate are often used to treat rheumatic diseases. They can also result in…